The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors
Abstract
Neuroendocrine tumors (NETs) of the digestive tract are a heterogeneous group of rare malignancies. Three major subgroups can be defined: pancreatic endocrine tumors, carcinoid tumors, and poorly differentiated gastroenteropancreatic NETs. Classically, digestive NETS have been considered to have an indolent course characterized for prolonged stabilizations or slow progressions, but there are clear differences in terms of aggressiveness, clinical course, and response to treatment among them. Retrospective studies have identified several clinicopathological and immunohistochemical factors as angioinvasion and proliferative index assessed by Ki-67 expression, which predict biological behavior and correlate with survival. Chemotherapy regimens based on the combination of several active drugs such as streptozocin, doxorubicin, 5-fluorouracil, dacarbazine, and temozolomide show low response rates, which sets the need to improve the results of the medical treatment of these malignancies. This review will analyze the role of Ki-67 in digestive NETs under a clinical perspective and will suggest future fields for development of this approach that enable a better patient selection for chemotherapy. Also a comprehensive review of the literature about chemotherapy in NETs is presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Cited by
Sorbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Holt, N., Osterlund, P., Dueland, S., Hofsli, E., Guren, M. G., Ohrling, K., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds276 · Cited by 1,027
Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
Kulke, M. H., Lenz, H.-J., Meropol, N. J., Posey, J., Ryan, D. P., Picus, J., Bergsland, E., Stuart, K., Tye, L., Huang, X., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9020 · Cited by 623
Jensen, R. T., Berna, M. J., Bingham, D. B., & Norton, J. A. (2008) · Cancer · doi:10.1002/cncr.23648 · Cited by 488
Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., Díaz-Pérez, J. A., Martínez del Prado, M. P., Alonso Orduña, V., Sevilla-García, I., Villabona-Artero, C., Beguiristain-Gómez, A., Llanos-Muñoz, M., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq022 · Cited by 419
Self-citationTumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor
Bettini, R., Partelli, S., Boninsegna, L., Capelli, P., Crippa, S., Pederzoli, P., Scarpa, A., & Falconi, M. (2011) · Surgery · doi:10.1016/j.surg.2011.02.022 · Cited by 358
Metadata
- Authors
- Vilar, E., Salazar, R., Pérez-García, J., Cortes, J., Öberg, K., & Tabernero, J.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2007-06
- Volume
- 14
- Issue
- 2
- Pages
- 221-232
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2159030747
- Cited by
- 161
- References
- 1
- FWCI
- 7.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. https://app.cochat.ai/papers/10.1677/erc-06-0074
- The paper
- Vilar, E., Salazar, R., Pérez-García, J., Cortes, J., Öberg, K., & Tabernero, J. (2007). Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer. https://doi.org/10.1677/erc-06-0074
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.